Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.50 |
| ▸ | LTA4H | P09960 | 2/20 | 0.49 |
| ▸ | PPARG | P37231 | 4/20 | 0.48 |
| ▸ | PPARA | Q07869 | 3/20 | 0.48 |
| ▸ | LAP3 | P28838 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.47 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.47 |
| ▸ | PPARD | Q03181 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.45 |
| ▸ | MME | P08473 | 1/20 | 0.44 |
| ▸ | ACE | P12821 | 1/20 | 0.44 |
| ▸ | CPA1 | P15085 | 1/20 | 0.44 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14963156 | 0.89 | ALDH1A1 (0.50) | LMNA | |
| SCHEMBL31001590 | 0.86 | LTA4H (0.54) | MAOBLTA4HPPARGPPARALAP3 | |
| SCHEMBL25901508 | 0.81 | LTA4H (0.65) | MAOBLTA4HPPARGPPARALAP3 | |
| SCHEMBL862827 | 0.80 | NR4A1 (0.57) | MAOBLMNAFAAH | |
| SCHEMBL27977003 | 0.80 | LTA4H (0.68) | MAOBLTA4HPPARGPPARALAP3 | |
| SCHEMBL21366441 | 0.80 | LTA4H (0.68) | MAOBLTA4HPPARGPPARALAP3 | |
| SCHEMBL22929153 | 0.80 | BCL2 (0.56) | — | |
| SCHEMBL18511388 | 0.79 | MGLL (0.42) | PPARAPPARDFAAHCPA1 | |
| SCHEMBL12324297 | 0.79 | ALOX12 (0.48) | LMNAL3MBTL1 | |
| SCHEMBL2749589 | 0.79 | GPR34 (0.59) | PPARGMMEACECPA1ACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234924-A1 | YAP1 INHIBITORS THAT TARGET THE INTERACTION OF YAP1 WITH OCT4 | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234924-A1 | YAP1 INHIBITORS THAT TARGET THE INTERACTION OF YAP1 WITH OCT4 | YAP1, YES1, MYC | MAOB 4496/4885LTA4H 4828/4885PPARG 3995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.